Tumor Heterogeneity Ubiquitous and Underestimated

R. Carlson

DOI: https://doi.org/10.1097/01.COT.0000466406.86933.cc

2015-05-01

Abstract:MIAMI BEACH—Heterogeneity in cancer genes is ubiquitous— between patients, within the primary tumor, between primary and metastasis, and even between metastases. “Heterogeneity is ubiquitous, it’s important, and I would argue that we routinely underestimate it,” said George W. Sledge, Jr, MD, Professor of Medicine and Chief of Medical Oncology at Stanford University School of Medicine, who outlined the implications of tumor heterogeneity in a presentation here at the Miami Breast Cancer Conference. “First, certainly at this point in the history of our field, we need to retest biomarkers that are of treatment relevance. Most of us already do this routinely when a patient develops metastatic disease, but perhaps we’re not doing it enough.” The ubiquity of heterogeneity also calls for a definition of what forms are clinically relevant. Sledge said some first steps have been taken in this direction, such as the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) Clinical Practice Guideline regarding heterogeneity (OT 11/10/2013 issue).

Medicine